NASDAQ:MIST Milestone Pharmaceuticals Q3 2025 Earnings Results & Report $0.77 -0.04 (-4.93%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$0.76 -0.01 (-0.76%) As of 08:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Milestone Pharmaceuticals beat analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.12 versus the -$0.17 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 12, 2025TimeBefore Market OpensConference Call7:00 AM ET Milestone Pharmaceuticals EPS ResultsActual EPS-$0.12Consensus EPS -$0.17Beat/MissBeat by +$0.05One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersMilestone Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsMilestone Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress ReleaseQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings ReleaseQuarterly Report(10-Q) Milestone Pharmaceuticals Q3 2025 Earnings FAQ Did Milestone Pharmaceuticals beat earnings estimates for Q3 2025? Milestone Pharmaceuticals (NASDAQ:MIST) reported earnings of -$0.12 per share for Q3 2025, beating the consensus estimate of -$0.17. The report was announced on Wednesday, November 12, 2025. When is Milestone Pharmaceuticals' next earnings date? Milestone Pharmaceuticals' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Milestone Pharmaceuticals on the company's earnings history page. Milestone Pharmaceuticals Earnings HeadlinesMilestone Moves Etripamil AFib-RVR Program Forward With First European Patient; Stock UpOctober 9, 2026 | rttnews.comMilestone Pharmaceuticals Enrolls First EU Patient in Phase 3 Etripamil Trial in Atrial FibrillationOctober 9, 2026 | finance.yahoo.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical TrialOctober 9, 2026 | globenewswire.comMilestone Enrolls First Canadian Patient In Phase 3 For EtripamilSeptember 27, 2026 | rttnews.comMilestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVRSeptember 24, 2026 | globenewswire.comSee More Milestone Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Milestone Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your email. Email Address About Milestone PharmaceuticalsMilestone Pharmaceuticals (NASDAQ:MIST) is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s lead product candidate is etripamil, a short-acting calcium channel blocker formulated as a nasal spray and designed for rapid, patient-administered treatment. Etripamil has been studied primarily for paroxysmal supraventricular tachycardia (PSVT), a condition characterized by episodes of abnormally rapid heart rate. The product is intended to provide patients with an option for treating episodes outside of a hospital or clinic, potentially reducing the need for emergency medical intervention. Milestone has also evaluated etripamil in other cardiovascular settings, including the management of certain blood-pressure-related conditions. Founded in 2013, Milestone Pharmaceuticals conducts its research and development activities in North America and has advanced etripamil through clinical development programs intended to support regulatory review. The company is headquartered in Montreal, Quebec, and has been led by President and Chief Executive Officer Joseph Oliveto.View Milestone Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
